Issue Brief
Consumer Survey - Disclosure of Industry Payments to Physicians
Jun 16, 2008
Americans want to know about physician ties to pharmaceutical companies. More info
Issue Brief
| Summary | Type |
|---|---|
Written Statement of Record Regarding the Sunshine Act by Dr. Daniel J. Carlat of the Pew Health GroupDr. Daniel Carlat, Director of the Pew Prescription Project, appeared before the U.S. Senate Special Committee on Aging to testify about the importance of implementing the Physician Payments Sunshine Act as quickly as possible. More info |
Issue Brief |
Time For ChangeAcademic medical centers (AMCs) form the intellectual core of medicine, training future doctors and researchers, and establishing standards that guide practicing physicians in the wider community. Where pharmaceutical industry marketing conflicts with the goals of patient care and professionalism, AMCs can provide leadership and guidance by establishing new standards on physician-industry relationships. More info |
Report |
Regulating Industry Payments to PhysiciansPhysicians write more than 2 billion prescriptions a year, an average of 7 for every American. Several states and the District of Columbia have enacted so-called “sunshine laws” setting limits on industry payments to physicians and/or requiring disclosure of the payments. Proposed legislation in both the U.S House and Senate would require industry to disclose “transfers of value” to physicians. More info |
Issue Brief |
Physician Payments Sunshine Provisions in Health Care ReformThe Physician Payments Sunshine provisions in health care reform legislation require drug and medical device manufacturers to publicly report gifts and payments made to physicians and teaching hospitals. More info |
Issue Brief |
PharmFree ScorecardMost of the 150 U.S. medical schools are failing when it comes to building strong conflict of interest policies to limit pharmaceutical marketing on campus, according to the American Medical Student Association (AMSA) PharmFree Scorecard released today. More info |
Report |
Pharmaceutical Industry MarketingReports of pharmaceutical and medical device industry marketing expenditures vary - pharmaceutical manufacturers spend billions annually on marketing - detailing, journal advertising, pharmaceutical samples and direct-to-consumer advertising. What can be done to protect patients, control health care costs, and bolster professionalism among physicians? The Prescription Project promotes a range of solutions for consumers, physicians, state and federal policy makers, and public and private payers. More info |
Issue Brief |
Pew Health Group comments on the implementation of Section 6002 of the Patient Protection and Affordable Care Act"The Pew Health Group of The Pew Charitable Trusts welcomes the opportunity to submit comments regarding the Centers for Medicare & Medicaid Services' ("CMS") proposed rule for Medicare, Medicaid, Children's Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Interests." More info |
Issue Brief |
Pew Comments on Centers for Medicaid and Medicare Services' Information Collection Activities Draft GuidanceThe Pew Charitable Trusts appreciates this opportunity to submit comments to CMS's "Information Collection Activities" draft guidance. We suggest that both the research and non-research payment templates be modified in order to make it easier for consumers to identify which drugs, devices, biologicals, or medical supplies are associated with particular transfers of value. More info |
Issue Brief |
Persuading the Prescribers: Pharmaceutical Industry Marketing and its Influence on Physicians and PatientsIn 2011, the pharmaceutical industry spent nearly $29 billion on drug promotion — more than $25 billion on marketing directly to physicians and almost $4 billion on advertising directly to consumers (mainly through television commercials). This multi-pronged approach is designed to promote its products by influencing doctors’ prescribing practices. More info |
Other Resource |
One Step Closer to Medical Transparency: Pew's Analysis of the Final Rule for the Physician Payments Sunshine ActOn Feb. 1, 2013, the Centers for Medicare & Medicaid Services published the final rule guiding implementation of the Physician Payments Sunshine Act, which Congress passed as part of the Affordable Care Act in March 2010 to increase transparency in the relationships between physicians and drug and medical device makers. Here are some of the highlights. More info |
Other Resource |
Non-physician Prescribers and Pharmaceutical Industry InteractionsIndustry marketing to non-physician prescribers has increased markedly in recent years to roughly 20 million detail visits in 2006, a 20% increase over 2004. More info |
Issue Brief |
MedPAC Recommendations - Public Reporting of Physicians' Financial RelationshipsFinal recommendations approved by commission on November 6, 2008 - five recommendations to Congress regarding legislation about disclosure of relationships and gifts and payments made to physicians from pharmaceutical and medical device/supply manufacturers. More info |
Issue Brief |
Letter from Pew to CMS Regarding Physician Payments Sunshine ActPrescription project director Danny Carlat identifies issues with the Physician Payments Sunshine Act requiring further clarification and guidance. Addressing those would ensure that manufacturers can appropriately implement the final rule, and enable consumers to benefit from transparency reports published by the Centers for Medicare & Medicaid Services. More info |
Issue Brief |
Legislative text of Physician Payment and other transparency provisions included in H.R. 3590Legislative text of Physician Payment and other transparency provisions included in H.R. 3590: Patient Protection and Affordable Care Act of 2009. Passed by the Senate (12/24/09) and the House (3/21/10). More info |
Issue Brief |
Joint Letter to HHS on Sunshine ImplementationDear Secretary Sebelius: We are writing to urge you to fully implement Section 1128G of the Social Security Act, the Physician Payments Sunshine Provision, which was added as Section 6002 of the Patient Protection and Affordable Care Act (PPACA). More info |
Issue Brief |
Allan Coukell
Daniel Carlat
